Key result
Global PAH-related DALY rate declined ~38% from 1990 to 2021 despite nearly doubled prevalence.
Why the study?
Pulmonary arterial hypertension poses significant clinical management challenges due to gaps in understanding its global epidemiology.
Observational (n=191,808)
Effect estimate: 37.9% reduction (-0.38 percent change) (95% CI -0.48 to -0.25)
Absolute Event Rate: 8.2% vs 13.2%
While global age-standardized rates for PAH-related DALYs and deaths have decreased since 1990, the absolute number of prevalent cases and deaths continues to rise significantly, with an increasing burden shifting toward older populations and high socio-demographic index (SDI) nations.
Pulmonary arterial hypertension (PAH) poses significant clinical management challenges due to gaps in understanding its global epidemiology. We analyzed PAH-related disability-adjusted life years (DALYs), deaths, and prevalence from 1990 to 2021. Age-period-cohort models and regression analyses assessed temporal trends and projected burdens to 2050. Globally, PAH-related DALYs declined by 6.6%, but increased by 13.9% in high socio-demographic index (SDI) countries. Middle SDI regions reported the highest DALYs in 1990 and 2021. Deaths rose by 48.5% worldwide, with high SDI nations experiencing a 76.6% surge. Age-standardized rates (ASRs) of DALYs and deaths decreased across SDI countries, with high-middle SDI regions showing the steepest declines. Younger age groups, especially males, had a higher proportion of global DALYs in earlier years, but the burden shifted toward older populations over time, with this trend more pronounced in high-SDI countries. Age-period-cohort analysis revealed declining DALYs in younger ages but rising rates in older cohorts. By 2050, deaths and prevalence are projected to rise, disproportionately affecting females. Significant regional disparities in PAH burden persist, necessitating targeted policies, improved healthcare access, and early detection strategies, especially in underserved areas. Addressing these disparities is critical for mitigating PAH' s global impact.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) conducted an observational in Pulmonary arterial hypertension (PAH) (n=191,808). Time period and Socio-demographic Index (SDI) vs. 1990 baseline was evaluated on Age-standardized rate (ASR) of Disability-Adjusted Life Years (DALYs) per 100,000 (37.9% reduction (-0.38 percent change), 95% CI -0.48 to -0.25). From 1990 to 2021, the global age-standardized rate of pulmonary arterial hypertension-related disability-adjusted life years declined by 37.9%, while the total prevalence nearly doubled to 191,808 cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: